Trial · NCT00290433

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

NCT00290433, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2020-09-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma. Trials, record NCT00290433. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00290433

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
NCT number: NCT00290433
Status: Completed
Phases: Phase 2
Enrollment: 55 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Lymphoma
Interventions: Cyclophosphamide, Mesna, Vincristine, Methotrexate, Ara-C, Dexamethasone, G-CSF, Doxil
First posted: 2006-02-13
Last updated: 2020-09-23
Results first posted: 2020-09-23

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	3 Year Progression-Free Survival Rate	From registration to disease progression or death, up to 3 years	Percentage of participants out of total treated alive with disease progression 3 years following registration. Progression-free survival (PFS) was measured from the date of study registration to the date of documented disease progression or death of any cause.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	3 Year Progression-Free Survival Rate	From registration to disease progression or death, up to 3 years	Of the 53 participants, \6 participants\ were not evaluable for response due to either no measurable disease (1) or early departure from study for adverse events (5)	percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
3 Year Progression-Free Survival Rate	HCVIDDOXIL Regimen		30	95% Confidence Interval 18 to 44	percentage of participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	HCVIDDOXIL Regimen	53
Overall Study	COMPLETED	HCVIDDOXIL Regimen	17
Overall Study	NOT COMPLETED	HCVIDDOXIL Regimen	36

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Neutropenia	Blood and lymphatic system disorders	HCVIDDOXIL Regimen	42	53	42
other	Anemia	Blood and lymphatic system disorders	HCVIDDOXIL Regimen	46	53	46
other	Thrombocytopenia	Blood and lymphatic system disorders	HCVIDDOXIL Regimen	46	53	46
other	Febrile Neutropenia	Blood and lymphatic system disorders	HCVIDDOXIL Regimen	21	53	21
other	Fever	General disorders	HCVIDDOXIL Regimen	35	53	35
other	Infectious Disease	Infections and infestations	HCVIDDOXIL Regimen	19	53	19
other	Fatigue	General disorders	HCVIDDOXIL Regimen	40	53	40
other	Liver Toxicities	Hepatobiliary disorders	HCVIDDOXIL Regimen	21	53	21
other	Constipation	Gastrointestinal disorders	HCVIDDOXIL Regimen	19	53	19
other	Dizziness	Nervous system disorders	HCVIDDOXIL Regimen	19	53	19

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	HCVIDDOXIL Regimen
Total, other adverse events	HCVIDDOXIL Regimen	46	53
Total, serious adverse events	HCVIDDOXIL Regimen	1	53

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
26260306	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00290433

GET https://conductscience.org/api/trials/v1/NCT00290433/registered

API reference For AI assistants